

PATENT

Attorney Docket No. 39766-0114

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application)	<u>PATENT APPLICATION</u>
)	
Inventor(s): Hans Koll, et al.)	
)	Art Unit: To Be Assigned
Application No.: 10/619,754)	
)	Examiner: To Be Assigned
Filed: July 14, 2003)	
)	
Title Methods for Identifying Tumors that are)	
Responsive to Treatment with Anti-ErbB2)	
Antibodies)	
)	

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and foreign patent is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98. In accordance with the Office's waiver of the filing requirement under 37 CFR 1.98 (a)(2)(i), for all U.S. national patent applications filed after June 30, 2003, copies of U.S. patents or U.S. patent application publication listed on the attached Form PTO-1449 are not enclosed.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. The Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

- ☒ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☒ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
- ☒ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; or
- ☐ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ **Fee Authorization.** The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No. 39766-0114).


Respectfully submitted,

HELLER EHRMAN WHITE & MCAULIFFE LLP


Dated: October 28, 2003

By: 
Ginger Dreger, Reg. No. 33,055


275 Middlefield Road
Menlo Park, CA 94025-3506
(650) 324-7000
Customer No. 25213

INFORMATION DISCLOSURE STATEMENT  PTO-1449			ATTY. DOCKET NO.		SERIAL NO.		
			39766-0114		10/619,754		
			APPLICANT Hans Koll, et al.				
FILING DATE July 14, 2003				GROUP: To Be Determined			
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	4,968,603	11/6/90	Slamon et al.	435	6		
	5,183,884	2/2/93	Kraus, et al.	536	23.5		
	5,480,968	2/2/96	Kraus, et al.	530	326		
	5,641,869	6/24/97	Vandlen et al.	530	413		
	5,677,171	10/14/97	Hudziak et al.	435	240.27		
	5,783,186	7/21/98	Arakawa	424	143.1		
	5,821,337	10/13/98	Carter et al.	530	387.3		
	5,824,311	10/20/98	Greene et al.	424	138.1		
	6,399,743	6/4/02	Majumdar	530	324		
	6,627,400	9/30/03	Singh et al.	435	6		
	2003/0096373	5/22/03	Majumdar et al.	435	70.21		
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	599,274	11/23/93	EP	C12N	15/12	<input type="checkbox"/>	<input type="checkbox"/>
	WO 01/00245	1/4/01	PCT	A61K	47/48	<input type="checkbox"/>	<input type="checkbox"/>
	WO 94/00136	1/6/94	PCT	A61K	35/14	<input type="checkbox"/>	<input type="checkbox"/>
	WO 94/22478	10/13/94	PCT	A61K	39/395	<input type="checkbox"/>	<input type="checkbox"/>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Aasland et al. "Expression of oncogenes in thyroid tumours: Coexpression of <i>c-erbB2/neu</i> and <i>c-erbB</i> " <i>Br. J. Cancer</i> 57:358-363 (1988)						
	Arteaga et al. "p185c-erbB-2 Signaling Enhances Cisplatin-induced Cytotoxicity in Human Breast Carcinoma Cells: Association between an Oncogenic Receptor Tyrosine Kinase and Drug-induced DNA Repair" <i>Cancer Research</i> 54:3758-3765 (1994)						
	Azzoli C.G. et al "Trastuzumab in the Treatment of Non-Small Cell Lung Cancer" <i>Seminars in Oncol</i> 29(1) Suppl 4:59-65 (2002)						
EXAMINER			DATE CONSIDERED				


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT 	ATTY. DOCKET NO. 39766-0114	SERIAL NO. 10/619,754
	APPLICANT Hans Koll, et al.	
	FILING DATE July 14, 2003	GROUP: To Be Determined
U.S. PATENT DOCUMENTS		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	Bacus et al. "Tumor-inhibitory Monoclonal Antibodies to the HER-2/Neu Receptor Induce Differentiation of Human Breast Cancer Cells" <i>Cancer Research</i> 52:2580-2589 (1992)	
	Bacus et al. "Differentiation of Cultured Human Breast Cancer Cells (AU-565 and MCF-7) Associated With Loss of Cell Surface HER-2/neu Antigen" <i>Molecular Carcinogenesis</i> 3:350-362 (1990)	
	Bange et al. "Molecular targets for breast cancer therapy and prevention" <i>Nature Medicine</i> 7(5):548-552 (2001)	
	Baselga et al. "Receptor Blockade with Monoclonal Antibodies as Anti-Cancer Therapy" <i>Pharmac. Ther.</i> 64:127-154 (1994)	
	Baselga et al. "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185her2 Monoclonal Antibody in Patients with HER2/neu-Overexpressing Metastatic Breast Cancer" <i>J Clin Oncol</i> 14(3):737-744 (1996)	
	Borst et al. "Oncogene Alterations in Endometrial Carcinoma" <i>Gynecol. Oncol.</i> 38:364 (1990)	
	Brennan P.J. et al. "HER2/Neu: mechanisms of dimerization/oligomerization" <i>Oncogene</i> 19:6093-6101 (2000)	
	Brockhoff et al. "Epidermal Growth Factor Receptor, c-erbB2 and c-erbB3 Receptor Interaction, and Related Cell Cycle Kinetics of SK-BR-3 and BT474 Breast Carcinoma Cells" <i>Cytometry</i> 44:338-348 (2001)	
	Carraway et al. "A Neu Acquaintance for ErbB3 and ErbB 4: A Role for Receptor Heterodimerization in Growth Signaling" <i>Cell</i> 78:5-8 (1994)	
	Carraway et al. "Neuregulin-2 a new ligand of ErbB3/ErbB4-receptor tyrosine kinases" <i>Nature</i> 387:512-516 (1997)	
	Chang et al. "Ligands for ErbB-family receptors encoded by a neuregulin-like gene" <i>Nature</i> 387:509-512 (1997)	
	Chen et al. "Tumor promoter arsenite activates extracellular signal-regulated kinase through a signaling pathway mediated by epidermal growth factor receptor and Shc" <i>Mol Cell Biol</i> 18(9): 5178-5188 (1998)	
	Chow et al. "Expression Profiles of ErbB Family Receptors and Prognosis in Primary Transitional Cell Carcinoma of the Urinary Bladder" <i>Clinical Cancer Research</i> 7:1975-1962 (2001)	
	Cohen et al. "Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract" <i>Oncogene</i> 4:81-88 (1989)	
	Clark et al. "Effects of tyrosine kinase inhibitors on the proliferation of human breast cancer cell lines and proteins important in the ras signaling pathway." <i>Intl. J. Cancer</i> 65:186-191 (1996)	
EXAMINER	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT  PTO-1449	ATTY. DOCKET NO. 39766-0114	SERIAL NO. 10/619,754
	APPLICANT Hans Koll, et al.	
	FILING DATE July 14, 2003	GROUP: To Be Determined
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	D'souza et al. "Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene" <i>PNAS (USA)</i> 91:7202-7206 (1994)	
	DiGiovanna et al. "Active Signaling by HER-2/neu in Subpopulation of HER-2/neu-overexpressing Ductal Carcinoma in Situ: Clinicopathological Correlates" <i>Cancer Research</i> 62:6667-6673 (2002)	
	Drebin et al. "Down-Modulation of an Oncogene Protein Product and Reversion of the Transformed Phenotype by Monoclonal Antibodies" <i>Cell</i> 41:695-706 (1985)	
	Drebin et al. "Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects" <i>Oncogene</i> 2:273-277 (1988)	
	Earp et al. "Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research" <i>Breast Cancer Research and Treatment</i> 35:115-132 (1995)	
	Esteva et al. "Expression of erbB/HER Receptors, Heregulin and P38 in Primary Breast Cancer using Quantitative Immunohistochemistry" <i>Path Oncol Res</i> 7(3):171-177 (2001)	
	Fendly et al. "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product" <i>Cancer Research</i> 50:1550-1558 (1990)	
	Fukushige et al. "Localization of a Novel v-erbB-Related Gene, c-erbB-2, on Human Chromosome 17 and Its Amplification in a Gastric Cancer Cell Line" <i>Mol and Cell Biol</i> 6(3):995-968 (1986)	
	Geurin et al. "Overexpression of Either c-myc or c-erbB-2/neu Proto-Oncogenes in Human Breast Carcinomas: Correlation with Poor Prognosis" <i>Oncogene Res</i> 3:21-31 (1988)	
	Graus-Porta et al. "ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling" <i>EMBO J</i> 16(7):1647-1655 (1997)	
	Groenen et al. "Structure-Function Relationships for the EGF/TGF- α Family of Mitogens" <i>Growth Factors</i> 11:235-257 (1994)	
	Gu et al. "Overexpression of her-2/neu in human prostate cancer and benign hyperplasia" <i>Cancer Letters</i> 99:185-189 (1996)	
	Hancock et al. "A Monoclonal Antibody against the c-erbB-2 Protein Enhances the Cytotoxicity of cis-Diamminedichloroplatinum against Human Breast and Ovarian Tumor Cell Lines" <i>Cancer Res</i> 51:4575-4580 (1991)	
	Harari et al. "Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase" <i>Oncogene</i> 18:2681-2689 (1999)	
	Harwerth et al. "Monoclonal Antibodies against the Extracellular Domain of the erbB-2 Receptor Function as a Partial Ligand Antagonists" <i>J. Biol Chem</i> 267:15160-15167 (1992)	
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PTO-1449 	ATTY. DOCKET NO. 39766-0114	SERIAL NO. 10/619,754
	APPLICANT Hans Koll, et al.	
	FILING DATE July 14, 2003	GROUP: To Be Determined
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	Holmes et al. "Identification of Heregulin, a Specific Activator of p185erbB2" <i>Science</i> 256:1205-1210 (1992)	
	<i>Horizons in Cancer Therapeutics: From Bench to Bedside</i> 2(2) (2001) Miniscus Educational Institute Pennsylvania (entire volume)	
	Hudziak et al. "p185HER2 Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor" <i>Mol Cel Biol</i> 9(3): 1165-1172 (1989)	
	Jong et al. "Mechanism of ErbB-1 and ErbB-2 Hetero-oligomerization" http://mrmc-rad6.army.mil/bcrp/era/abstracts2002/P21_EGF_Superfamily/P21_combined.pdf	
	Kasprzyk et al. "Therapy of an Animal Model of Human Gastric Cancer Using a Combination of Anti-erbB-2 Monoclonal Antibodies" <i>Cancer Research</i> 52:2771-2776 (1992)	
	Kern et al. "p185neu Expression in Human Lung Adenocarcinomas Predicts Shortened Survival" <i>Cancer Res.</i> 50:5184 (1990)	
	King et al. "Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma" <i>Science</i> 229:974 (1985)	
	Klapper et al. "A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 block crosstalk with growth factor receptors" <i>Oncogene</i> 14:2099-2109 (1997)	
	Kotts et al. "Differential Growth Inhibition of Human Carcinoma Cells exposed to Monoclonal Antibodies Directed against the Extracellular Domain of the HER2/ERBB2" <i>In Vitro</i> 26(3):59A (1990)	
	Kraus et al. "Isolation and characterization of ERBB3 a third member of the ERBB/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors" <i>PNAS (USA)</i> 86:9193-9197 (1989)	
	Kumar et al. "Regulation of Phosphorylation of the c-erbB-2/Her2 Gene Product by a Monoclonal Antibody and Serum Growth Factor(s) in Human Mammary Carcinoma Cells" <i>Mol and Cell Biol</i> 11(2):979-986 (1991)	
	Lee et al. "Transforming Growth Factor α : Expression Regulation and Biological Activities" <i>Pharm Rev</i> 47:51-85 (1995)	
	Lemke G. "Review Neuregulins in Development" <i>Mol and Cell Neurosci</i> 7:247-262 (1996)	
	Levi et al. "The Influence of Heregulins on Human Schwann Cell Proliferation" <i>Journal of Neuroscience</i> 15(2):1329-1340 (1995)	
	Lewis et al. "Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies" <i>Cancer Immunol. Immunother</i> 37:255-263 (1993)	
EXAMINER	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 39766-0114	SERIAL NO. 10/619,754
	APPLICANT Hans Koll, et al.	
	FILING DATE July 14, 2003	GROUP: To Be Determined
U.S. PATENT DOCUMENTS		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	Lewis et al. "Growth Regulation of Human Brest and Ovarian Tumor Cells by Heregulin: Evidence for the Requirement of ErbB2 as a Critical Component in Mediating Heregulin Responsiveness" <i>Cancer Research</i> 56:1457-1465 (1996)	
	Maier et al. "Requirements for the Internalization of a Murine Monoclonal Antibody Directed against the HER-2/neu Gene Product c-erbB-2" <i>Cancer Res</i> 51:5361-5369 (1991)	
	Masui et al. "Growth Inhibition of Human Tumor Cells in Athymic Mice by Antiepidermal Growth Factor Receptor Monoclonal Antibodies" <i>Cancer Research</i> 44:1002-1007 (1984)	
	McCann et al. "c-erbB-2 Oncoprotein Expression in Primary Human Tumors" <i>Cancer</i> 65:88-92 (1990)	
	McKenzie et al. "Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185" <i>Oncogene</i> 4:543-548 (1989)	
	Meric et al. "ZD1839 "Iressa"" <i>Bull Cancer</i> 87(12):873-876 (2000)	
	Mitchell "Peptide Regulatory Factors Post-Receptor Signaling Pathways" <i>Lancet</i> 1:765-767 (1989)	
	Moasser et al. "The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells" <i>Cancer Res.</i> 61(19):7184-7188 (2001)	
	Morrissey et al. "Axon-induced mitogenesis of human Schwann cells involves heregulin and p185erbB2" <i>PNAS USA</i> 92:1431-1435 (1995)	
	Myers et al. "Biological Effects of Monoclonal Antireceptor Antibodies Reactive with neu Oncogene Products p185neu" <i>Meth. Enzym.</i> 198:277-290 (1991)	
	Nagy et al. "EGF-Induced Redistribution of erbB2 on Breast Tumor Cells: Flow and Image Cytometric Energy Treansfer Measurements" <i>Cytometry</i> 32:120-131 (1998)	
	Norman P. "OSI-774 OSI Pharmaceuticals" <i>Curr. Opin. Investig. Drugs</i> 2(2):298-304 (2001)	
	Nomanno et al. "Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth" <i>Ann. Oncol.</i> 13:65-72 (2002)	
	Park et al. "Amplification, Overexpression, and Rearrangement of the erbB-2 Protooncogene in Primary Human Stomack Carcinomas" <i>Cancer Res</i> 49:6605-6609 (1989)	
	Pietras et al. "Antibody ot HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells" <i>Oncogene</i> 9:1829-1838 (1994)	
	Plowman et al "Heregulin induces tyrosine phosphorylation of HER4/p180erbB4" <i>Nature</i> 366:473-475 (1993)	
EXAMINER	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 39766-0114	SERIAL NO. 10/619,754
	APPLICANT Hans Koll, et al.	
	FILING DATE July 14, 2003	GROUP: To Be Determined
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	Plowman et al. "Ligand-specific activation of HER4/p180erbB4 a fourth member of the epidermal growth factor receptor family" <i>PNAS USA</i> 90:1746-1750 (1993)	
	Olayioye et al. "The ErbB signaling network: receptor heterodimerization in development and cancer" <i>EMBO Journal</i> 19(13):3159-3167 (2000)	
	<i>Oncology Biotherapeutics Anti-EGFR therapy: A new targeted approach to cancer treatment</i> 2(1) (2002) Cancer Communications Limited, Germany (entire volume)	
	Partik et al. "Inhibition of epidermal-growth-factor-receptor-dependent signaling by tyrphostins A25 and AG1478 block growth and induces apoptosis in colorectal tumor cells in vitro" <i>J. Cancer Res Clin Oncol.</i> 125: 379-388 (1999)	
	Pollack et al. "Inhibitions of epidermal growth factor receptor-associated tyrosinophosphorylation in human carcinomas with CP-358, 774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice" <i>JPET</i> 291(2):739-748 (1999)	
	Raymond et al. "Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy" <i>Drugs</i> 60(Suppl 1):15-23; discussion 41-42 (2000)	
	Ross et al. "Prognostic Singificance of HER-2/neu Gene Amplification Status by Florescence in Situ Hybridization of Prostate Carinoma" <i>Cancer</i> 79:2162-2170	
	Ross et al. "HER-2/neu Gene Amplification Status in Prostate Cancer by Florescence in Situ Hybridization" <i>Hum. Pathol.</i> 28(7):827-833 (1997)	
	Sadasivan et al. "Overexpression of HER-2/Neu may be an indication of poor prognosis in prostate cancer" <i>J. Urol.</i> 150:126-131 (1993)	
	Sarup et al. "Characterization of an Anti-p185HER2 Monoclonal Antibody that Stimulates Receptor Function and Inhibits Tumor Cell Growth" <i>Growth Regulation</i> 1:72-82 (1991)	
	Schaefer et al. "γ-Heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175" <i>Oncogene</i> 15:1385-1394 (1997)	
	Scott et al. "p185HER2 Signal Transduction in Breast Cancer Cells" <i>J. Biol Chem</i> 266(22):14300-14305 (1991)	
	Sewell, et al. "Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD1839 ("Iressa")" <i>Br. J. Cancer</i> 86(3):456-462 (2000)	
	Shawver et al. "Ligand-like Effects Induced by Anti-c-erbB-2 Antibodies Do Not Correlate With And Are Not Required For Growth Inhibition Of Human Carcinoma Cells" <i>Cancer Res.</i> 54:1367-1373 (1994)	
	Shepard et al. "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protoonogene to the Clinic" <i>J. Clin. Immunology</i> 11(3):117-127 (1991)	
EXAMINER	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 39766-0114	SERIAL NO. 10/619,754
	APPLICANT Hans Koll, et al.	
	FILING DATE July 14, 2003	GROUP: To Be Determined
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	Slamon et al. "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ <i>neu</i> Oncogene" <i>Science</i> 235:177-182 (1987)	
	Slamon et al. "Studied of the HER-2/ <i>neu</i> Proto-oncogene in Human Breast and Ovarian Cancer" <i>Science</i> 244:707-712 (1989)	
	Sliwkowski et al "Coexpression of erbB2 and erbB3 Proteins Reconstitutes a High Affinity Receptor for Heregulin" <i>J. Biol Chem</i> 269(20):14661-14665 (1994)	
	Stancovski et al. "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth" <i>PNAS (USA)</i> 88:8691-8695 (1991)	
	"Structure-function relationship of EGF-like growth factors" www-celbi.sci.kun.nl/project1.htm (6/25/03)	
	Tagliabue et al. "Selection of Monoclonal Antibodies which Induce Internalization and Phosphorylation of p185HER2 and Growth Inhibition of Cells with HER2/ <i>neu</i> Gene Amplification" <i>Int J Cancer</i> 47:933-937 (1991)	
	Tang C. "Coexpression of EGFRvIII/ErbB in Human Breast Cancer" http://dcb.nci.nih.gov/abstract.cfm?ID=6522728 (Abstract only)	
	Thor et al. "Activation (Tyrosine Phosphorylation) of ErbB-2 (HER-2/ <i>neu</i>): A Study of Incidence and Correlation with Outcome in Breast Cancer" <i>J. of Clin. Onc.</i> 18(18):3230-3239 (2000)	
	Vitetta et al. "Monoclonal Antibodies as Agonists: An Expanded Role for Their Use in Cancer Therapy" <i>Cancer Research</i> 54:5301-5309 (1994)	
	Weiner et al. "Expression of the <i>neu</i> Gene-encoded Protein (P185 <i>neu</i>) in Human Non-Small Cell Carcinomas of the Lung" <i>Cancer Res.</i> 50:421-425 (1990)	
	Williams et al. "Expression of c-erbB-2 in Human Pancreatic Adenocarcinomas" <i>Pathobiology</i> 59:46-52 (1991)	
	Wu et al. "Apoptosis Induced by an Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in a Human Colorectal Carcinoma Cell Line and Its Delay by Insulin" <i>J. Clin. Invest.</i> 95:1897-1905 (1995)	
	Xia et al. "Combination of EGFR, HER-2/ <i>neu</i> and HER-3 Is a Stronger Predictor for the Outcome of Oral Squamous Cell Carcinoma Than Any Individual Family Members" <i>Clinical Cancer Research</i> 5:4164-4174 (1999)	
	Xu et al. "Antibody-Induced Growth Inhibition is Mediated Through Immunochemically and Functionally Distinct Epitopes on the Extracellular Domain of the c-erbB-2 (HER-2/ <i>neu</i>) GeneProduct p185" <i>Int J. Cancer</i> 53:401-408 (1993)	
EXAMINER	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 39766-0114	SERIAL NO. 10/619,754
	APPLICANT Hans Koll, et al.	
	FILING DATE July 14, 2003	GROUP: To Be Determined
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	Yarden "ErbB-2 ErbB-3 Heterodimeric Receptor of Carcinomas" http://dcb.nci.nih.gov/abstract.cfm?ID=6513047 (Abstract only)	
	Yonemura et al "Evaluation of Immunoreactivity for erbB-2 Protein as a marker of Poor Short Term Prognosis in Gastric Cancer" <i>Cancer Res</i> 51:1034-1038 (1991)	
	Zhau et al. "Amplification and Expression of the c-erb B-2/ <i>neu</i> Proto-Oncogene in Human Bladder Cancer" <i>Mol. Carcinog.</i> 3:254-257 (1990)	
	Zhang et al. "New Perspectives on Anti-Her2/ <i>neu</i> Therapeutics" <i>Drug News Perspect</i> 13(6):325-329 (2000)	
	Zhang et al. "Neuregulin-3 (NRG3): A novel neural tissue-enriched protein that binds and activates ErbB4" <i>PNAS (USA)</i> 94:9562-9567 (1997)	
EXAMINER	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.